Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
Trial details
- Registry ID
- NCT04652882
- Phase
- Phase 3
The FDA approved Tasimelteon on 31 Jan 2014.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882 | Vanda Pharmaceuticals | Phase 3 | Completed | 2026-09-04Actual |
| Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantNCT06701396 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2025-06-30Estimated |
| Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaNCT03373201 | Vanda Pharmaceuticals | Phase 3 | Completed | 2018-03-05Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-01-31Day | Tasimelteon | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA205677", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["HETLIOZ"], "active_ingredients": ["TASIMELTEON"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140131", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |